Megha Tollefson, MD – Mayo Clinic and Amy Paller, MD – Northwestern University
Children on anti-TNF agents have been reported to develop psoriasis, but the majority of the literature is in the gastrointestinal (GI) literature and focuses on infliximab and inflammatory bowel disease. Not much is known about other primary disease processes and other medications, nor risk factors to develop this paradoxical reaction. This study is a retrospective multi-center review to further characterize this process.
Enrollment is complete, and a manuscript is being prepared for publication